TRVI News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TR

Mkt Cap

$1.69B

Volume

2.33M

Next Earnings

November 12th

Loading chart

TR

TRVITrevi Therapeutics, Inc. Common Stock

TRVI

Pay with—

Available Balance0.00

TR

Mkt Cap

$1.69B

Volume

2.33M

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Trevi Therapeutics to Participate in Upcoming August ConferencesTrevi Therapeutics announced that senior management will participate in two biotech conferences in August 2026, including Oppenheimer's Biotech in the Berkshires on August 4 and Stifel's 2026 Biotech Summer Summit on August 10-12. The company is developing Haduvio (oral nalbuphine ER) for treating chronic cough in patients with IPF, non-IPF ILD, and RCC, with clinical trials showing statistically significant reductions in cough frequency.GlobeNewswire Inc. · Jul 28, 2026

Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common StockTrevi Therapeutics priced an underwritten public offering of 11.6 million shares at $13.00 per share, raising approximately $150 million before underwriting costs. The clinical-stage biopharmaceutical company is developing Haduvio (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis and other lung conditions. The offering is expected to close on April 20, 2026.Benzinga · Apr 17, 2026

Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common StockTrevi Therapeutics priced an underwritten public offering of 11.6 million shares at $13.00 per share, raising approximately $150 million before fees. The clinical-stage biopharmaceutical company is developing Haduvio (oral nalbuphine ER) for chronic cough treatment in IPF, non-IPF ILD, and refractory chronic cough patients. The offering is expected to close on April 20, 2026.GlobeNewswire Inc. · Apr 17, 2026

Chronic Refractory Cough Market is Expected to Boom by 2034 Driven by Advancements in Treatment Options | DelveInsightThe chronic refractory cough market is projected to expand by 2034, driven by rising patient diagnoses, improved awareness, and emerging therapies targeting refractory cough conditions.GlobeNewswire Inc. · Nov 24, 2025

TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the FirmLaw firm Kaskela Law LLC is investigating Trevi Therapeutics for potential securities law violations or breaches of fiduciary duties, encouraging long-term investors to contact them for more information.GlobeNewswire Inc. · Jun 26, 2025

Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightThe pulmonary fibrosis market is driven by the increasing prevalence of the disease, especially idiopathic pulmonary fibrosis, among the aging population. Innovations in drug development and diagnostics, favorable reimbursement policies, and greater awareness are fueling market growth. The pipeline appears robust with over 110 active players working on 120+ pipeline drugs.GlobeNewswire Inc. · Jan 28, 2025

Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock NowTrevi Therapeutics (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.Zacks Investment Research · Apr 18, 2024

Why Trevi Therapeutics (TRVI) Stock Might be a Great PickTrevi Therapeutics (TRVI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.Zacks Investment Research · Apr 4, 2024

Trevi Therapeutics, Inc. (TRVI) Upgraded to Strong Buy: Here's WhyTrevi Therapeutics, Inc. (TRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).Zacks Investment Research · Jan 17, 2024

The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocksA more selective small-cap index has consistently outperformed the Russell 2000MarketWatch · Jan 6, 2024

to start trading

TR

TRVITrevi Therapeutics, Inc. Common Stock

TRVI

Pay with—

Available Balance0.00

Your PositionYou don't own any TRVI yet.

Related Tickers

Earnings